Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29276822 | 0.93 | GPR119 (0.52) | GPR119HRH3CHEK2ALDH1A1PDE4B | |
| SCHEMBL29276820 | 0.93 | GPR119 (0.52) | GPR119HRH3CHEK2ALDH1A1PDE4B | |
| SCHEMBL31031682 | 0.93 | GPR119 (0.52) | GPR119HRH3CHEK2ALDH1A1PDE4B | |
| SCHEMBL215713 | 0.90 | GPR119 (0.57) | GPR119HRH3CHEK2KDM1AALDH1A1 | |
| SCHEMBL21570073 | 0.90 | GPR119 (0.57) | GPR119HRH3CHEK2KDM1AALDH1A1 | |
| SCHEMBL214556 | 0.89 | GPR119 (0.56) | GPR119HRH3CHEK2KDM1AALDH1A1 | |
| SCHEMBL16514077 | 0.89 | GPR119 (0.67) | GPR119HRH3CHEK2KDM1AALDH1A1 | |
| SCHEMBL29990082 | 0.89 | GPR119 (0.56) | GPR119HRH3CHEK2KDM1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL9013879 | 0.89 | GPR119 (0.56) | GPR119HRH3CHEK2KDM1AALDH1A1 | |
| SCHEMBL27087770 | 0.89 | GPR119 (0.56) | GPR119HRH3CHEK2KDM1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | GPR119 2016/4885HRH3 1553/4885CHEK2 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.